Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.

[1]  A. Blom,et al.  Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. , 2015, Molecular immunology.

[2]  J. Andersen,et al.  Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. , 2015, Immunobiology.

[3]  R. Porcher,et al.  Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. , 2015, Blood.

[4]  G. Ardissino,et al.  Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  Francesco Tedesco,et al.  Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. , 2014, Blood.

[6]  G. Ardissino,et al.  Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome , 2014, Journal of thrombosis and haemostasis : JTH.

[7]  J. Pu,et al.  Successful discontinuation of eculizumab therapy in a patient with aHUS , 2014, Annals of Hematology.

[8]  A. M. Shaw,et al.  Electroluminescent TCC, C3dg and fB/Bb epitope assays for profiling complement cascade activation in vitro using an activated complement serum calibration standard. , 2014, Journal of immunological methods.

[9]  D. Kavanagh,et al.  Complement therapy in atypical haemolytic uraemic syndrome (aHUS) , 2013, Molecular immunology.

[10]  P. Hillmen,et al.  Thrombosis in paroxysmal nocturnal hemoglobinuria. , 2013, Blood.

[11]  G. Remuzzi,et al.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. , 2013, The New England journal of medicine.

[12]  S. Cataland,et al.  Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation , 2013, Annals of Hematology.

[13]  G. Rijkers,et al.  Meningococcal Sepsis Complicating Eculizumab Treatment Despite Prior Vaccination , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  V. Frémeaux-Bacchi,et al.  Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies , 2012, Nature Reviews Nephrology.

[15]  E. Volokhina,et al.  Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding , 2012, Pediatric Nephrology.

[16]  C. Sautès-Fridman,et al.  A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. , 2012, Blood.

[17]  J. Wetzels,et al.  A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. , 2012, The Netherlands journal of medicine.

[18]  M. Harboe,et al.  Advances in assay of complement function and activation. , 2011, Advanced drug delivery reviews.

[19]  L. Monnens,et al.  Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy , 2011, Pediatric Nephrology.

[20]  T. Mollnes,et al.  Recurrent meningococcal sepsis in a presumptive immunocompetent host shown to be complement C5 deficient—a case report , 2011, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[21]  A. Waters,et al.  aHUS caused by complement dysregulation: new therapies on the horizon , 2010, Pediatric Nephrology.

[22]  Giuseppe Remuzzi,et al.  Atypical hemolytic-uremic syndrome. , 2009, The New England journal of medicine.

[23]  T. Jokiranta,et al.  Mutations of Factor H Impair Regulation of Surface-bound C3b by Three Mechanisms in Atypical Hemolytic Uremic Syndrome* , 2009, The Journal of Biological Chemistry.

[24]  W. Fridman,et al.  Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. , 2008, Blood.

[25]  A. Salar,et al.  An Observational Study of Anaemia Management in Patients with NHL Receiving CHOP-14 or -21 (With or Without Rituximab) , 2008 .

[26]  P. Zipfel,et al.  Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. , 2008, Blood.

[27]  P. Zipfel,et al.  Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. , 2008, Blood.

[28]  R. Brodsky,et al.  Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.

[29]  B. Paul Morgan,et al.  Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome , 2007, Proceedings of the National Academy of Sciences.

[30]  G. Remuzzi,et al.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. , 2006, Blood.

[31]  J. Goodship,et al.  Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. , 2005, Journal of the American Society of Nephrology : JASN.

[32]  A. Buil,et al.  Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. , 2005, Human molecular genetics.

[33]  W. Fridman,et al.  Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome , 2004, Journal of Medical Genetics.

[34]  G. Remuzzi,et al.  Familial haemolytic uraemic syndrome and an MCP mutation , 2003, The Lancet.

[35]  J. Goodship,et al.  Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Walport.  Complement. First of two parts. , 2001, The New England journal of medicine.

[37]  Wiklund Ra,et al.  First of two parts , 1997 .

[38]  Henry P. Treffers,et al.  Complement , 1966, The Yale Journal of Biology and Medicine.

[39]  J. Stockman.  Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome , 2011 .